145 related articles for article (PubMed ID: 15899618)
1. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
Magné N; Milano G
Bull Cancer; 2004 Dec; 91 Suppl 4():S257-60. PubMed ID: 15899618
[TBL] [Abstract][Full Text] [Related]
2. The role of the epidermal growth factor receptor in breast cancer.
Chan SK; Hill ME; Gullick WJ
J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):3-11. PubMed ID: 16947082
[TBL] [Abstract][Full Text] [Related]
3. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
4. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Nielsen DL; Andersson M
Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
[TBL] [Abstract][Full Text] [Related]
5. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
6. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
Emlet DR; Brown KA; Kociban DL; Pollice AA; Smith CA; Ong BB; Shackney SE
Mol Cancer Ther; 2007 Oct; 6(10):2664-74. PubMed ID: 17938260
[TBL] [Abstract][Full Text] [Related]
7. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
8. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
10. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
11. [Management of metastatic HER2-positive breast cancer: present and future].
Guiu S; Coudert B; Favier L; Arnould L; Fumoleau P
Bull Cancer; 2010 Mar; 97(3):365-83. PubMed ID: 20176546
[TBL] [Abstract][Full Text] [Related]
12. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
[TBL] [Abstract][Full Text] [Related]
13. [Targeting ErbB receptors in breast cancer].
Fumoleau P; Campone M; Coudert B; Mayer F; Favier L; Ferrant E
Bull Cancer; 2007; 94(7 Suppl):F147-70. PubMed ID: 17964992
[TBL] [Abstract][Full Text] [Related]
14. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
Slamon DJ
Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
[No Abstract] [Full Text] [Related]
15. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
16. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
18. [Targeting epidermal growth factor receptor in cancer of the breast].
Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
20. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
